Janssen Search
Search results
Partnerships
COVID-19 News Redirect Tile BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research Collaborating with Karolinska Institutet for Advanced Real-World Data Analysis Joining Forces to Fight Chagas ...
New Research Platforms
Three New Research Platforms Focused on Redefining Healthcare Article Type: World Without Disease Accelerator Disease Interception Accelerator In early 2015, Janssen Research & Development launched three new research platforms that focus on disease ...
About World Without Disease Accelerator
About the World Without Disease Accelerator Our Mission Consistent with Johnson & Johnson’s transformational medical innovation strategy, the mission of the World Without Disease Accelerator (WWDA) is to discover, develop and prepare for the ...
Finding Value Through the Product Lifecycle
Article Type: Oncology Establishing and Capturing Value Throughout the Product Lifecycle At Janssen, getting our medicines to patients who will benefit is our mission and why we exist. From a market access perspective, this means that, very early in the ...
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
Sep 16, 2024 Spain TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, September 16, 2024 – Johnson & Johnson (NYSE:JNJ) ...
Partners in Precision Medicine
Our Focus on Collaborations and Partnerships We believe that innovation can come from anywhere and is often the result of unified efforts from multiple collaborators. Janssen has a demonstrated appreciation for the value of collaboration and partnership, ...
Measuring and Maintaining Health
Measuring and Maintaining Health Our research starts with healthy people and explores health rather than disease. We search for prevention markers, which are biological measures of health status and risk. Prevention markers will direct our future search ...
Meredith Hans Moore, Ph.D.
MEREDITH HANS MOORE, PH.D. GLOBAL VICE PRESIDENT IMMUNOLOGY MEDICAL AFFAIRS Meredith Hans Moore, Ph.D., is the Global Vice President, Immunology Medical Affairs. In this role, Meredith is responsible for the medical strategy, data dissemination and ...
Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with the completion of the acquisition of Yellow Jersey Therapeutics, gaining ownership of NM26
Jul 11, 2024 NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune ...
Social Media Dashboard
Follow Janssen on Social Media We know that our customers, partners, colleagues and others with an interest in our company are active on social media sites. We want to be part of those conversations so that we can hear and discuss ideas, help answer ...